We are currently developing oral and ophthalmic drug candidates for the treatment of patients with unmet medical needs in respiratory and ophthalmic diseases.

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a rare disease that mainly occurs after the age of 60. IPF is a chronic, progressive disease characterised by damage to the lungs, which become fibrosed and are no longer able to breathe properly. It progresses to chronic respiratory failure. The median survival rate for patients is around 3 years after diagnosis. It is thought to affect between 5,500 and 9,000 people in France, and more than 200,000 in Europe and the United States. To date, there is no cure for this disease.

Dry Eye and Gougerot-Sjögren’s syndrome

Dry eye syndrome is caused by poor quality or insufficient production of tear fluid, which increases the risk of eye infection and inflammation. This syndrome affects more than 300 million people worldwide. Gougerot-Sjögren's syndrome is a rare disease affecting 2.5 million people worldwide. Its symptoms are linked to the infiltration of certain glands by lymphocytes, leading to a reduction in their secretion. The lacrimal glands are among the most commonly affected, resulting in a "dry syndrome".